Company intelligence / Profile preview

Neuro3 Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Neuro3 recently licensed from Lundbeck two clinical-stage and one preclinical KCNQ2 activator programs and is responsible for development through clinical proof-of-concept in epilepsy and other CNS diseases; detailed clinical results have not yet been disclosed.

Therapeutic areas: Neurology
Modalities: Small moleculeRNA therapy
Industry: Biotech

Drug pipeline

1 asset

Neuro-3

Preclinical

Partnerships

Lundbeck (exclusive worldwide license and option agreement for KCNQ2 activators, with options for co-development, co-commercialization, and territory-specific licenses)

Beyond the preview

Go deeper on Neuro3 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuro3 Therapeutics.

Explore the full profile